Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer

Gynecologic Oncology

Volumn 96, Issue 1, 2005, Pages 132-135

  Micha, John P ^a   Goldstein, Bram H ^a   Mattison, Julie A ^a   Bader, Kathy ^a   Graham, Cheri ^a   Rettenmaier, Mark A ^a   Brown, John V ^a   Markman, Maurie ^b  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carboplatin paclitaxel gemcitabine primary chemotherapy; Consolidation therapy; Gynecologic oncology; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 10044280462     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.10.001     Document Type: Article

References (20)

1. D.A. Fishman, J. O'Rourke, N. Karnik, D. Singh, and L. Cohen Will high-tech tests revolutionize the early detection of ovarian cancer? Contemp. OB/GYN 38 2003 44 52
2. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. A Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3194 3200
3. J.V. Brown, M.A. Rettenmaier, R.A. Dillman, C.L. Birk, K. Culkin, and J.P. Micha Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer Gynecol. Oncol. 68 1998 166 168
4. K. Bertelsen, A. Jakobsen, J. Stroyer, K. Nielsen, E. Sandberg, and J.E. Andersen A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group (DACOVA) trial Gynecol. Oncol. 49 1993 30 36
5. H.E. Lambert, G.J. Rustin, W.M. Gregory, and A.E. Nelstrop A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. North Thames Ovary Group Study Ann. Oncol. 8 1997 327 333
6. G.H. Eltabbakh, M.S. Piver, R.E. Hempling, F.O. Recio, and L.E. Blumenson Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum sensitive ovarian cancer Gynecol. Oncol. 71 1998 190 195
7. M. Markman, P.Y. Liu, S. Wilczynski, B. Monk, L.J. Copeland, and R.D. Alvarez Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J. Clin. Oncol. 21 2003 2460 2465
8. J. Rohl, D. Kushner, and M. Markman Chronic administration of single agent paclitaxel in gynecologic malignancies Gynecol. Oncol. 81 2001 201 205
9. P. Dufour, J.-P. Bergerat, C. Giron, B. Duclos, and P. Dellenbach Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian cancer in pathologic complete remission Cancer 73 1994 1865 1869
10. R.R. Barakat, L. Almadrones, E.S. Venkatraman, C. Aghajanian, C. Brown, and F. Shapiro A Phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment Gynecol. Oncol. 69 1998 17 22
11. C. Tournigand, C. Louvet, J.L. Molitor, X. Fritel, N. Dehni, and A. Sezeur Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission Gynecol. Oncol. 91 2003 341 345
12. E.K. Rowinsky, and R.C. Donehower Paclitaxel (Taxol) N. Engl. J. Med. 332 1995 1004 1014
13. M. Markman, T. Hakes, R. Barakat, J. Curtin, L. Almadrones, and W. Hoskins Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on NCI treatment referral center protocol 9103: paclitaxel in refractory ovarian cancer J. Clin. Oncol. 14 1996 796 799
14. M. Markman, and M.A. Bookman Second-line treatment of ovarian cancer Oncologist 5 2000 26 35
15. M. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol. Oncol. 90 2003 593 596
16. J.D. Hainsworth, and F. Greco Paclitaxel administered by 1-hour infusion Cancer 74 1994 1377 1382
17. WHO handbook for reporting results for cancer treatment 1979 World Health Organization Geneva
18. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J. Clin. Oncol. 19 2001 4054 4057
19. J.P. Micha, B.H. Goldstein, M.A. Rettenmaier, J. Mattison, C. Graham, and C.L. Birk Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer Gynecol. Oncol. 94 2004 719 724
20. M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson, and L. Van Le Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer J. Clin. Oncol. 20 2002 2365 2369